相关实验视频

Updated: Jun 29, 2025

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

通过分子向疗法进行的跨动脉化学栓塞,再加上用于复发性肝细胞癌的卡梅利祖马布

Changlong Hou^1,2, Baizhu Xiong^3,4, Lei Zhou³

¹Department of Intervention, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, 107# Huanhu East Road, Shushan District, 230031, Hefei, Anhui, People's Republic of China. houchanglong2022@126.com.

|March 28, 2024

概括

将camrelizumab添加到跨动脉化学栓塞以及分子向治疗中,显著改善了复发性肝细胞癌患者的结果. 这种组合疗法增强了瘤反应,延长了生存期,提供了更好的预后.

科学领域:

肝病学肝病学是一种肝病学.
在瘤学瘤学.
干预性放射学干预性放射学

背景情况:

通过动脉化学栓塞 (TACE) 加上免疫检查点抑制剂 (ICI) 的分子向疗法 (MTT) 在原发性肝癌中显示出有前途.
在复发性肝细胞癌 (RHCC) 中这种组合的证据有限.
在RHCC中评估TACE + MTT + ICI对于它们在原发性疾病中的有效性至关重要.

研究的目的:

评估TACE加MTT与camrelizumab (一种ICI) 结合在患有复发性肝细胞癌 (RHCC) 的患者中的疗效和安全性.
为了比较这种组合疗法与TACE加MTT单独用于RHCC治疗.

主要方法:

对88名RHCC患者的回顾性分析.
患者接受TACE + MTT + camrelizumab (TACE-TC 组,n=46) 或TACE + MTT (TACE-T 组,n=42) 的治疗.
评估的结果包括瘤反应,无进展生存期 (PFS),总生存期 (OS) 和不良事件 (AE).

主要成果:

与TACE-T组相比,TACE-TC组表现出优异的PFS (14.0 vs. 8.9个月) 和OS (31.1 vs. 20.2个月) 与TACE-T组相比.
此外,TACE-TC还显示了更高的疾病控制率 (89.1%与71.4%) 和客观反应率 (47.8%与26.2%).
在TACE-TC组,AFP水平显著下降;在3-4级AE中没有发现显著差异.

结论:

联合治疗TACE,MTT和camrelizumab显著改善了RHCC的瘤反应.
这种治疗方案延长了生存时间,这表明RHCC患者的生存预后更好.
用TACE + MTT + camrelizumab治疗是复发性肝细胞癌的安全有效选择.

关键词:

肝细胞癌是肝细胞癌.免疫检查点抑制剂免疫检查点抑制剂干预性治疗是一种干预性治疗.有针对性的治疗.通过动脉化学栓塞的超动脉化疗.

更多相关视频

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...